Oral administration of Parabacteroides distasonis antigens attenuates experimental murine colitis through modulation of immunity and microbiota composition

Clinical and Experimental Immunology

Volumn 163, Issue 2, 2011, Pages 250-259

  Kverka, M ^a   Zakostelska, Z ^a   Klimesova, K ^a   Sokol, D ^a   Hudcovic, T ^b   Hrncir, T ^b   Rossmann, P ^a   Mrazek, J ^a   Kopecny, J ^a   Verdu, E F ^c   Tlaskalova Hogenova, H ^a  

^a INSTITUTE OF MATHEMATICS   (Czech Republic)

^b Novy Hradek   (Czech Republic)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

Animal models; Cytokines interleukins; DSS colitis; Inflammatory bowel disease; Microbiota

Indexed keywords

DEXTRAN SULFATE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 6; PROBIOTIC AGENT; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANAEROBIC BACTERIUM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COLITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG EFFECT; FEMALE; IMMUNOMODULATION; INTESTINE FLORA; MOUSE; NONHUMAN; PARABACTEROIDES DISTASONIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SCID MOUSE;

ACUTE DISEASE; ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTEROIDES; CHRONIC DISEASE; COLITIS; CYTOKINES; FEMALE; INTESTINAL MUCOSA; METAGENOME; MICE; MICE, INBRED BALB C; MICE, SCID;

EID: 78650803767     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2010.04286.x     Document Type: Article

References (45)

1. Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology 2008; 134:577-94.
2. Seksik P, Sokol H, Lepage P et al. Review article: the role of bacteria in onset and perpetuation of inflammatory bowel disease. Aliment Pharmacol Ther 2006; 24 (Suppl. 3):11-18.
3. Rutgeerts P, Goboes K, Peeters M et al. Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet 1991; 338:771-4.
4. Prantera C, Scribano ML. Antibiotics and probiotics in inflammatory bowel disease: why, when, and how. Curr Opin Gastroenterol 2009; 25:329-33.
5. Hudcovic T, Stepankova R, Cebra J, Tlaskalova-Hogenova H. The role of microflora in the development of intestinal inflammation: acute and chronic colitis induced by dextran sulfate in germ-free and conventionally reared immunocompetent and immunodeficient mice. Folia Microbiol (Praha) 2001; 46:565-72.
6. Rath HC, Herfarth HH, Ikeda JS et al. Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats. J Clin Invest 1996; 98:945-53.
7. Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, Horak I. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993; 75:253-61.
8. Stepankova R, Powrie F, Kofronova O et al. Segmented filamentous bacteria in a defined bacterial cocktail induce intestinal inflammation in SCID mice reconstituted with CD45RBhigh CD4+ T cells. Inflamm Bowel Dis 2007; 13:1202-11.
9. Taurog JD, Richardson JA, Croft JT et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 1994; 180:2359-64.
10. Seksik P, Rigottier-Gois L, Gramet G et al. Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon. Gut 2003; 52:237-42.
11. Scanlan PD, Shanahan F, O'Mahony C, Marchesi JR. Culture-independent analyses of temporal variation of the dominant fecal microbiota and targeted bacterial subgroups in Crohn's disease. J Clin Microbiol 2006; 44:3980-8.
12. Van Assche G, Vermeire S, Rutgeerts P. Safety issues with biological therapies for inflammatory bowel disease. Curr Opin Gastroenterol 2006; 22:370-6.
13. Mahida YR, Rolfe VE. Host-bacterial interactions in inflammatory bowel disease. Clin Sci (Lond) 2004; 107:331-41.
14. Bibiloni R, Fedorak RN, Tannock GW et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 2005; 100:1539-46.
15. Kruis W, Fric P, Pokrotnieks J et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004; 53:1617-23.
16. Mimura T, Rizzello F, Helwig U et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004; 53:108-14.
17. Seksik P, Dray X, Sokol H, Marteau P. Is there any place for alimentary probiotics, prebiotics or synbiotics, for patients with inflammatory bowel disease? Mol Nutr Food Res 2008; 52:906-12.
18. Kokesova A, Frolova L, Kverka M et al. Oral administration of probiotic bacteria (E. coli Nissle, E. coli O83, Lactobacillus casei) influences the severity of dextran sodium sulfate-induced colitis in BALB/c mice. Folia Microbiol (Praha) 2006; 51:478-84.
19. Obermeier F, Dunger N, Strauch UG et al. Contrasting activity of cytosin-guanosin dinucleotide oligonucleotides in mice with experimental colitis. Clin Exp Immunol 2003; 134:217-24.
20. Rachmilewitz D, Katakura K, Karmeli F et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 2004; 126:520-8.
21. Verdu EF, Bercik P, Cukrowska B et al. Oral administration of antigens from intestinal flora anaerobic bacteria reduces the severity of experimental acute colitis in BALB/c mice. Clin Exp Immunol 2000; 120:46-50.
22. Westphal O, Lüderitz O, Bister F. Extraction of bacteria with phenol/water. Z Naturforsch 1952; 7b:148-55.
23. Ali IK, Zaki M, Clark CG. Use of PCR amplification of tRNA gene-linked short tandem repeats for genotyping Entamoeba histolytica. J Clin Microbiol 2005; 43:5842-7.
24. Murano M, Maemura K, Hirata I et al. Therapeutic effect of intracolonically administered nuclear factor kappa B (p65) antisense oligonucleotide on mouse dextran sulphate sodium (DSS)-induced colitis. Clin Exp Immunol 2000; 120:51-8.
25. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990; 98:694-702.
26. Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 1993; 69:238-49.
27. Monteleone G, Peluso I, Fina D et al. Bacteria and mucosal immunity. Dig Liver Dis 2006; 38 (Suppl. 2):S256-60.
28. Tlaskalova-Hogenova H, Stepankova R, Hudcovic T et al. Commensal bacteria (normal microflora), mucosal immunity and chronic inflammatory and autoimmune diseases. Immunol Lett 2004; 93:97-108.
29. Williams AM, Probert CS, Stepankova R, Tlaskalova-Hogenova H, Phillips A, Bland PW. Effects of microflora on the neonatal development of gut mucosal T cells and myeloid cells in the mouse. Immunology 2006; 119:470-8.
30. Petnicki-Ocwieja T, Hrncir T, Liu YJ et al. Nod2 is required for the regulation of commensal microbiota in the intestine. Proc Natl Acad Sci USA 2009; 106:15813-18.
31. Salzman NH, Hung K, Haribhai D et al. Enteric defensins are essential regulators of intestinal microbial ecology. Nat Immunol 2010; 11:76-83.
32. Dieleman LA, Ridwan BU, Tennyson GS, Beagley KW, Bucy RP, Elson CO. Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. Gastroenterology 1994; 107:1643-52.
33. Grabig A, Paclik D, Guzy C et al. Escherichia coli strain Nissle 1917 ameliorates experimental colitis via Toll-like receptor 2- and Toll-like receptor 4-dependent pathways. Infect Immun 2006; 74:4075-82.
34. Atreya R, Mudter J, Finotto S et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat Med 2000; 6:583-8.
35. Wang F, Graham WV, Wang Y, Witkowski ED, Schwarz BT, Turner JR. Interferon-gamma and tumor necrosis factor-alpha synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression. Am J Pathol 2005; 166:409-19.
36. Hrncir T, Stepankova R, Kozakova H, Hudcovic T, Tlaskalova-Hogenova H. Gut microbiota and lipopolysaccharide content of the diet influence development of regulatory T cells: studies in germ-free mice. BMC Immunol 2008; 9:65.
37. Sokol H, Pigneur B, Watterlot L et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA 2008; 105:16731-6.
38. Okada Y, Tsuzuki Y, Miyazaki J et al. Propionibacterium freudenreichii component 1.4-dihydroxy-2-naphthoic acid (DHNA) attenuates dextran sodium sulphate induced colitis by modulation of bacterial flora and lymphocyte homing. Gut 2006; 55:681-8.
39. Mazmanian SK, Round JL, Kasper DL. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 2008; 453:620-5.
40. Papadakis KA, Targan SR. Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology 2000; 119:1148-57.
41. Siddiqui MA, Scott LJ. Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis. Drugs 2005; 65:2179-208.
42. Adams RJ, Heazlewood SP, Gilshenan KS, O'Brien M, McGuckin MA, Florin TH. IgG antibodies against common gut bacteria are more diagnostic for Crohn's disease than IgG against mannan or flagellin. Am J Gastroenterol 2008; 103:386-96.
43. Slack E, Hapfelmeier S, Stecher B et al. Innate and adaptive immunity cooperate flexibly to maintain host-microbiota mutualism. Science 2009; 325:617-20.
44. Keilbaugh SA, Shin ME, Banchereau RF et al. Activation of RegIIIbeta/gamma and interferon gamma expression in the intestinal tract of SCID mice: an innate response to bacterial colonisation of the gut. Gut 2005; 54:623-9.
45. Singh B, Read S, Asseman C et al. Control of intestinal inflammation by regulatory T cells. Immunol Rev 2001; 182:190-200.